Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 54 entries
Sorted by: Best Match Show Resources per page
[No title available]

Open forum infectious diseases

Doyle L, Vogel S, Procop GW.
PMID: 29062861
Open Forum Infect Dis. 2017 Sep 02;4(4):ofx193. doi: 10.1093/ofid/ofx193. eCollection 2017.

BACKGROUND: The testing strategy for METHODS: We reviewed the results of all RESULTS: Toluidine blue staining and surgical pathology had similar sensitivities and negative predictive values, both of which were superior to cytology. There was a >4-fold increase in...

Cite
Doyle L, Vogel S, Procop GW. . Open Forum Infect Dis. 2017;4(4):ofx193doi: 10.1093/ofid/ofx193.
Doyle, L., Vogel, S., & Procop, G. W. (2017). . Open forum infectious diseases, 4(4), ofx193. https://doi.org/10.1093/ofid/ofx193
Doyle, Laura, et al. "." Open forum infectious diseases vol. 4,4 (2017): ofx193. doi: https://doi.org/10.1093/ofid/ofx193
Doyle L, Vogel S, Procop GW. . Open Forum Infect Dis. 2017 Sep 02;4(4):ofx193. doi: 10.1093/ofid/ofx193. eCollection 2017. PMID: 29062861; PMCID: PMC5641380.
Copy Download .nbib Format: NLM
Insights into N-calls of mitochondrial DNA sequencing using MitoChip v2.0.

BMC research notes

Zamzami MA, Price GR, Taylor RW, Blakely EL, Oancea I, Bowling F, Duley JA.
PMID: 22011414
BMC Res Notes. 2011 Oct 20;4:426. doi: 10.1186/1756-0500-4-426.

BACKGROUND: Developments in DNA resequencing microarrays include mitochondrial DNA (mtDNA) sequencing and mutation detection. Failure by the microarray to identify a base, compared to the reference sequence, is designated an 'N-call.' This study re-examined the N-call distribution of mtDNA...

Cite
Zamzami MA, Price GR, Taylor RW, et al. Insights into N-calls of mitochondrial DNA sequencing using MitoChip v2.0. BMC Res Notes. 2011;4:426doi: 10.1186/1756-0500-4-426.
Zamzami, M. A., Price, G. R., Taylor, R. W., Blakely, E. L., Oancea, I., Bowling, F., & Duley, J. A. (2011). Insights into N-calls of mitochondrial DNA sequencing using MitoChip v2.0. BMC research notes, 4426. https://doi.org/10.1186/1756-0500-4-426
Zamzami, Mazin A, et al. "Insights into N-calls of mitochondrial DNA sequencing using MitoChip v2.0." BMC research notes vol. 4 (2011): 426. doi: https://doi.org/10.1186/1756-0500-4-426
Zamzami MA, Price GR, Taylor RW, Blakely EL, Oancea I, Bowling F, Duley JA. Insights into N-calls of mitochondrial DNA sequencing using MitoChip v2.0. BMC Res Notes. 2011 Oct 20;4:426. doi: 10.1186/1756-0500-4-426. PMID: 22011414; PMCID: PMC3208482.
Copy Download .nbib Format: NLM
Antibiotic prophylaxis in retrograde ureteroscopy: what strategy should we adopt?.

Germs

Pricop C, Dorobăt C, Puia D, Orsolya M.
PMID: 24432295
Germs. 2013 Dec 01;3(4):115-21. doi: 10.11599/germs.2013.1045. eCollection 2013 Dec 01.

BACKGROUND: Retrograde ureteroscopy as a minimally invasive treatment of ureteral calculi can be complicated by the occurrence of urinary tract infections. Fever is considered the main indicator of such postoperative complications and we aimed to study its incidence in...

Cite
Pricop C, Dorobăt C, Puia D, et al. Antibiotic prophylaxis in retrograde ureteroscopy: what strategy should we adopt?. Germs. 2013;3(4):115-21doi: 10.11599/germs.2013.1045.
Pricop, C., Dorobăt, C., Puia, D., & Orsolya, M. (2013). Antibiotic prophylaxis in retrograde ureteroscopy: what strategy should we adopt?. Germs, 3(4), 115-21. https://doi.org/10.11599/germs.2013.1045
Pricop, Cătălin, et al. "Antibiotic prophylaxis in retrograde ureteroscopy: what strategy should we adopt?." Germs vol. 3,4 (2013): 115-21. doi: https://doi.org/10.11599/germs.2013.1045
Pricop C, Dorobăt C, Puia D, Orsolya M. Antibiotic prophylaxis in retrograde ureteroscopy: what strategy should we adopt?. Germs. 2013 Dec 01;3(4):115-21. doi: 10.11599/germs.2013.1045. eCollection 2013 Dec 01. PMID: 24432295; PMCID: PMC3882851.
Copy Download .nbib Format: NLM
Evaluation of the Rosemary Extract Effect on the Properties of Polylactic Acid-Based Materials.

Materials (Basel, Switzerland)

Darie-Niţă RN, Vasile C, Stoleru E, Pamfil D, Zaharescu T, Tarţău L, Tudorachi N, Brebu MA, Pricope GM, Dumitriu RP, Leluk K.
PMID: 30257509
Materials (Basel). 2018 Sep 25;11(10). doi: 10.3390/ma11101825.

New multifunctional materials containing additives derived from natural resources as powdered rosemary ethanolic extract were obtained by melt mixing and processed in good conditions without degradation and loss of additives. Incorporation of powdered rosemary ethanolic extract (R) into poly(lactic...

Cite
Darie-Niţă RN, Vasile C, Stoleru E, et al. Evaluation of the Rosemary Extract Effect on the Properties of Polylactic Acid-Based Materials. Materials (Basel). 2018;11(10)doi: 10.3390/ma11101825.
Darie-Niţă, R. N., Vasile, C., Stoleru, E., Pamfil, D., Zaharescu, T., Tarţău, L., Tudorachi, N., Brebu, M. A., Pricope, G. M., Dumitriu, R. P., & Leluk, K. (2018). Evaluation of the Rosemary Extract Effect on the Properties of Polylactic Acid-Based Materials. Materials (Basel, Switzerland), 11(10), . https://doi.org/10.3390/ma11101825
Darie-Niţă, Raluca Nicoleta, et al. "Evaluation of the Rosemary Extract Effect on the Properties of Polylactic Acid-Based Materials." Materials (Basel, Switzerland) vol. 11,10 (2018). doi: https://doi.org/10.3390/ma11101825
Darie-Niţă RN, Vasile C, Stoleru E, Pamfil D, Zaharescu T, Tarţău L, Tudorachi N, Brebu MA, Pricope GM, Dumitriu RP, Leluk K. Evaluation of the Rosemary Extract Effect on the Properties of Polylactic Acid-Based Materials. Materials (Basel). 2018 Sep 25;11(10). doi: 10.3390/ma11101825. PMID: 30257509; PMCID: PMC6213757.
Copy Download .nbib Format: NLM
G-Quartet hydrogels for effective cell growth applications.

Chemical communications (Cambridge, England)

Rotaru A, Pricope G, Plank TN, Clima L, Ursu EL, Pinteala M, Davis JT, Barboiu M.
PMID: 29131208
Chem Commun (Camb). 2017 Nov 23;53(94):12668-12671. doi: 10.1039/c7cc07806d.

Functional G-quartet hydrogels formed from natural guanosine cross linked with benzene-1,4-diboronic acid and Mg

Cite
Rotaru A, Pricope G, Plank TN, et al. G-Quartet hydrogels for effective cell growth applications. Chem Commun (Camb). 2017;53(94):12668-12671doi: 10.1039/c7cc07806d.
Rotaru, A., Pricope, G., Plank, T. N., Clima, L., Ursu, E. L., Pinteala, M., Davis, J. T., & Barboiu, M. (2017). G-Quartet hydrogels for effective cell growth applications. Chemical communications (Cambridge, England), 53(94), 12668-12671. https://doi.org/10.1039/c7cc07806d
Rotaru, Alexandru, et al. "G-Quartet hydrogels for effective cell growth applications." Chemical communications (Cambridge, England) vol. 53,94 (2017): 12668-12671. doi: https://doi.org/10.1039/c7cc07806d
Rotaru A, Pricope G, Plank TN, Clima L, Ursu EL, Pinteala M, Davis JT, Barboiu M. G-Quartet hydrogels for effective cell growth applications. Chem Commun (Camb). 2017 Nov 23;53(94):12668-12671. doi: 10.1039/c7cc07806d. PMID: 29131208.
Copy Download .nbib Format: NLM
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.

RMD open

Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Mpofu S, Pricop L.
PMID: 30167329
RMD Open. 2018 Aug 13;4(2):e000723. doi: 10.1136/rmdopen-2018-000723. eCollection 2018.

OBJECTIVE: To assess the long-term (3 year) efficacy and safety of secukinumab in patients with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study (NCT01892436).METHODS: Following the 2-year core trial, eligible patients receiving subcutaneous secukinumab...

Cite
Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018;4(2):e000723doi: 10.1136/rmdopen-2018-000723.
Mease, P. J., Kavanaugh, A., Reimold, A., Tahir, H., Rech, J., Hall, S., Geusens, P., Pellet, P., Delicha, E. M., Mpofu, S., & Pricop, L. (2018). Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD open, 4(2), e000723. https://doi.org/10.1136/rmdopen-2018-000723
Mease, Philip J, et al. "Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial." RMD open vol. 4,2 (2018): e000723. doi: https://doi.org/10.1136/rmdopen-2018-000723
Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Mpofu S, Pricop L. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018 Aug 13;4(2):e000723. doi: 10.1136/rmdopen-2018-000723. eCollection 2018. PMID: 30167329; PMCID: PMC6109799.
Copy Download .nbib Format: NLM
Diagnostic utility of urine cytology in early detection of polyomavirus in transplant patients.

Journal of the American Society of Cytopathology

Xing J, Procop GW, Reynolds JP, Chiesa-Vottero A, Zhang Y.
PMID: 31042631
J Am Soc Cytopathol. 2017 Jan - Feb;6(1):28-32. doi: 10.1016/j.jasc.2016.08.004. Epub 2016 Aug 20.

INTRODUCTION: Polyomavirus-associated nephropathy (PVAN) is one of the most common disease affecting transplant patients, mainly caused by BK polyomavirus (BKV) and with

Cite
Xing J, Procop GW, Reynolds JP, et al. Diagnostic utility of urine cytology in early detection of polyomavirus in transplant patients. J Am Soc Cytopathol. 2016;6(1):28-32doi: 10.1016/j.jasc.2016.08.004.
Xing, J., Procop, G. W., Reynolds, J. P., Chiesa-Vottero, A., & Zhang, Y. (2017). Diagnostic utility of urine cytology in early detection of polyomavirus in transplant patients. Journal of the American Society of Cytopathology, 6(1), 28-32. https://doi.org/10.1016/j.jasc.2016.08.004
Xing, Juan, et al. "Diagnostic utility of urine cytology in early detection of polyomavirus in transplant patients." Journal of the American Society of Cytopathology vol. 6,1 (2017): 28-32. doi: https://doi.org/10.1016/j.jasc.2016.08.004
Xing J, Procop GW, Reynolds JP, Chiesa-Vottero A, Zhang Y. Diagnostic utility of urine cytology in early detection of polyomavirus in transplant patients. J Am Soc Cytopathol. 2017 Jan - Feb;6(1):28-32. doi: 10.1016/j.jasc.2016.08.004. Epub 2016 Aug 20. PMID: 31042631.
Copy Download .nbib Format: NLM
The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin-Characterization and Biocompatibility in Mice.

Antibiotics (Basel, Switzerland)

Hilițanu LN, Mititelu-Tarțău L, Popa GE, Buca BR, Pavel LL, Pelin AM, Meca AD, Bogdan M, Pricop DA.
PMID: 34943683
Antibiotics (Basel). 2021 Nov 30;10(12). doi: 10.3390/antibiotics10121471.

Nanoantibiotics have proved improved pharmacokinetic characteristics and antimicrobial features. Recent studies have shown non-toxicity, non-immunogenicity, antioxidant, anti-hyperlipidemic, and hepatocyte protective actions, among other advantages of chitosan-based nanoparticles. The purpose of our study was the structural analysis of novel chitosan-coated...

Cite
Hilițanu LN, Mititelu-Tarțău L, Popa GE, et al. The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin-Characterization and Biocompatibility in Mice. Antibiotics (Basel). 2021;10(12)doi: 10.3390/antibiotics10121471.
Hilițanu, L. N., Mititelu-Tarțău, L., Popa, G. E., Buca, B. R., Pavel, L. L., Pelin, A. M., Meca, A. D., Bogdan, M., & Pricop, D. A. (2021). The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin-Characterization and Biocompatibility in Mice. Antibiotics (Basel, Switzerland), 10(12), . https://doi.org/10.3390/antibiotics10121471
Hilițanu, Loredana Nicoleta, et al. "The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin-Characterization and Biocompatibility in Mice." Antibiotics (Basel, Switzerland) vol. 10,12 (2021). doi: https://doi.org/10.3390/antibiotics10121471
Hilițanu LN, Mititelu-Tarțău L, Popa GE, Buca BR, Pavel LL, Pelin AM, Meca AD, Bogdan M, Pricop DA. The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin-Characterization and Biocompatibility in Mice. Antibiotics (Basel). 2021 Nov 30;10(12). doi: 10.3390/antibiotics10121471. PMID: 34943683.
Copy Download .nbib Format: NLM
The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin-Characterization and Biocompatibility in Mice.

Antibiotics (Basel, Switzerland)

Hilițanu LN, Mititelu-Tarțău L, Popa GE, Buca BR, Pavel LL, Pelin AM, Meca AD, Bogdan M, Pricop DA.
PMID: 34943683
Antibiotics (Basel). 2021 Nov 30;10(12). doi: 10.3390/antibiotics10121471.

Nanoantibiotics have proved improved pharmacokinetic characteristics and antimicrobial features. Recent studies have shown non-toxicity, non-immunogenicity, antioxidant, anti-hyperlipidemic, and hepatocyte protective actions, among other advantages of chitosan-based nanoparticles. The purpose of our study was the structural analysis of novel chitosan-coated...

Cite
Hilițanu LN, Mititelu-Tarțău L, Popa GE, et al. The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin-Characterization and Biocompatibility in Mice. Antibiotics (Basel). 2021;10(12)doi: 10.3390/antibiotics10121471.
Hilițanu, L. N., Mititelu-Tarțău, L., Popa, G. E., Buca, B. R., Pavel, L. L., Pelin, A. M., Meca, A. D., Bogdan, M., & Pricop, D. A. (2021). The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin-Characterization and Biocompatibility in Mice. Antibiotics (Basel, Switzerland), 10(12), . https://doi.org/10.3390/antibiotics10121471
Hilițanu, Loredana Nicoleta, et al. "The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin-Characterization and Biocompatibility in Mice." Antibiotics (Basel, Switzerland) vol. 10,12 (2021). doi: https://doi.org/10.3390/antibiotics10121471
Hilițanu LN, Mititelu-Tarțău L, Popa GE, Buca BR, Pavel LL, Pelin AM, Meca AD, Bogdan M, Pricop DA. The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin-Characterization and Biocompatibility in Mice. Antibiotics (Basel). 2021 Nov 30;10(12). doi: 10.3390/antibiotics10121471. PMID: 34943683.
Copy Download .nbib Format: NLM
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.

The British journal of dermatology

Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM, Bao W, Pellet P, Pricop L, McInnes IB.
PMID: 33913511
Br J Dermatol. 2021 Dec;185(6):1124-1134. doi: 10.1111/bjd.20413. Epub 2021 Jul 14.

BACKGROUND: Secukinumab [an interleukin (IL)-17A inhibitor] has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL-12/23 inhibitor) in patients with moderate-to-severe plaque psoriasis.OBJECTIVES: To report 52-week results from a prespecified analysis of patients...

Cite
Gottlieb AB, Merola JF, Reich K, et al. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. Br J Dermatol. 2021;185(6):1124-1134doi: 10.1111/bjd.20413.
Gottlieb, A. B., Merola, J. F., Reich, K., Behrens, F., Nash, P., Griffiths, C. E. M., Bao, W., Pellet, P., Pricop, L., & McInnes, I. B. (2021). Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. The British journal of dermatology, 185(6), 1124-1134. https://doi.org/10.1111/bjd.20413
Gottlieb, A B, et al. "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study." The British journal of dermatology vol. 185,6 (2021): 1124-1134. doi: https://doi.org/10.1111/bjd.20413
Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM, Bao W, Pellet P, Pricop L, McInnes IB. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. Br J Dermatol. 2021 Dec;185(6):1124-1134. doi: 10.1111/bjd.20413. Epub 2021 Jul 14. PMID: 33913511.
Copy Download .nbib Format: NLM
Resistance and Virulence Features of .

Pathogens (Basel, Switzerland)

Pricop GR, Gheorghe I, Pircalabioru GG, Cristea V, Popa M, Marutescu L, Chifiriuc MC, Mihaescu G, Bezirtzoglou E.
PMID: 33198093
Pathogens. 2020 Nov 12;9(11). doi: 10.3390/pathogens9110940.

Anaerobic bacteria are predominant residents of the normal microbiota of the skin and mucous membranes but are also known to be associated with a number of human infections including peritonitis, appendicitis, abscesses, ulcers and wound infections. Herein, we investigate...

Cite
Pricop GR, Gheorghe I, Pircalabioru GG, et al. Resistance and Virulence Features of . Pathogens. 2020;9(11)doi: 10.3390/pathogens9110940.
Pricop, G. R., Gheorghe, I., Pircalabioru, G. G., Cristea, V., Popa, M., Marutescu, L., Chifiriuc, M. C., Mihaescu, G., & Bezirtzoglou, E. (2020). Resistance and Virulence Features of . Pathogens (Basel, Switzerland), 9(11), . https://doi.org/10.3390/pathogens9110940
Pricop, Gabriela Roxana, et al. "Resistance and Virulence Features of ." Pathogens (Basel, Switzerland) vol. 9,11 (2020). doi: https://doi.org/10.3390/pathogens9110940
Pricop GR, Gheorghe I, Pircalabioru GG, Cristea V, Popa M, Marutescu L, Chifiriuc MC, Mihaescu G, Bezirtzoglou E. Resistance and Virulence Features of . Pathogens. 2020 Nov 12;9(11). doi: 10.3390/pathogens9110940. PMID: 33198093; PMCID: PMC7696418.
Copy Download .nbib Format: NLM
Varicella Zoster Virus and Large Vessel Vasculitis, the Absence of an Association.

Pathogens & immunity

Procop GW, Eng C, Clifford A, Villa-Forte A, Calabrese LH, Roselli E, Svensson L, Johnston D, Pettersson G, Soltesz E, Lystad L, Perry JD, Blandford A, Wilson DA, Hoffman GS.
PMID: 28758156
Pathog Immun. 2017;2(2):228-238. doi: 10.20411/pai.v2i2.196. Epub 2017 Jun 06.

OBJECTIVE: It is controversial whether microorganisms play a role in the pathogenesis of large and medium vessel vasculitides (eg, giant cell arteritis [GCA], Takayasu arteritis [TAK] and focal idiopathic aortitis [FIA]). Recent studies have reported the presence of Varicella...

Cite
Procop GW, Eng C, Clifford A, et al. Varicella Zoster Virus and Large Vessel Vasculitis, the Absence of an Association. Pathog Immun. 2017;2(2):228-238doi: 10.20411/pai.v2i2.196.
Procop, G. W., Eng, C., Clifford, A., Villa-Forte, A., Calabrese, L. H., Roselli, E., Svensson, L., Johnston, D., Pettersson, G., Soltesz, E., Lystad, L., Perry, J. D., Blandford, A., Wilson, D. A., & Hoffman, G. S. (2017). Varicella Zoster Virus and Large Vessel Vasculitis, the Absence of an Association. Pathogens & immunity, 2(2), 228-238. https://doi.org/10.20411/pai.v2i2.196
Procop, Gary W, et al. "Varicella Zoster Virus and Large Vessel Vasculitis, the Absence of an Association." Pathogens & immunity vol. 2,2 (2017): 228-238. doi: https://doi.org/10.20411/pai.v2i2.196
Procop GW, Eng C, Clifford A, Villa-Forte A, Calabrese LH, Roselli E, Svensson L, Johnston D, Pettersson G, Soltesz E, Lystad L, Perry JD, Blandford A, Wilson DA, Hoffman GS. Varicella Zoster Virus and Large Vessel Vasculitis, the Absence of an Association. Pathog Immun. 2017;2(2):228-238. doi: 10.20411/pai.v2i2.196. Epub 2017 Jun 06. PMID: 28758156; PMCID: PMC5531613.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 54 entries